Biosimilars developer mAbxience has today officially opened a monoclonal antibodies facility in León, Spain, following a EUR25million (US $28million) investment.
Having paid around EUR11 million last year to adquire the former Genhelix plant in León (Generics Bulletin, 20 june 2014, page 3), mAbxience has since spent another EUR14 million on upgrading the 16,000 sq m site to meet the needs of its biosimilars pipeline. This included installing single-use technology such as disponsable bioreactors to maximise the facility´s flexibility and eliminate the potencial for cross-contamination. Furthermore, mAbxience says single-use technology reduces consumption of water and cleaning agents by 80% and 90% respectively, as they are not required to clean bioreactors.
Generics Bulletin 16/10/2015